Oligonucleotide CDMOs: Pioneering the Future of Precision Therapeutics
As the biotechnology and pharmaceutical industries pivot toward precision medicine and targeted therapies, the role of oligonucleotide contract development and manufacturing organizations (CDMOs) is entering a phase of profound strategic relevance. No longer relegated to the periphery, oligonucleotide CDMOs are emerging as critical enablers of innovation, scalability, and commercialization in a market...